The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 19)
Research Grant, 2017
Previous research has shown higher levels of the c-Abl protein are activated in the brains of people with Parkinson's disease (PD), and studies have linked c-Abl to pathways associated with the disease. Impeding the activity of this protein could potentially slow or stop the progression of PD, making it an emerging therapeutic target. While much work remains to understand the role ...
Researchers: Tanya Simuni, MD
Research Grant, 2016
GBA Meta-analysis Initiative: Charting a Path to Success for Clinical Trials in Patients with GBA-PD
Promising Outcomes of Original Grant:
We ascertained the associations between GBA mutations and cognitive and motor outcomes in seven large cohorts representing 2,304 patients with PD (including 221 carrying a GBA mutation) and 20,868 longitudinal study visits conducted in England, the Netherlands, France, Canada and the United States. This study found that GBA mutations hasten the longitudinal pro...
Therapeutic Pipeline Program, 2015
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson's disease (PD) worldwide. The purpose of this research is to test a new treatment (Telephone-Administered Cognitive Behavioral Therapy or T-CBT) for depression in PD. The treatment does not involve medication but teac...
Researchers: Roseanne D. Dobkin, PhD
Research Grant, 2014
Apomorphine is a drug that is used to control "off" episodes in people with Parkinson's disease. At present, the drug is given by injection under the skin and starts to relieve symptoms within 20-30 minutes. APL-130277 is a new formulation of apomoprhine that is given as a thin-strip film that is placed under the tongue. APL-130277 appears to work as quickly as t...
Researchers: Albert Agro, PhD
LRRK2 Biology LEAPS, 2012
Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates
Much recent work has suggested that comprehending the biological properties of an enzyme termed LRRK2 that is mutated in about one percent of all Parkinson's disease patients, will be crucial for better understanding of the molecular causes of Parkinson's disease as well as designing new strategies to better treat this condition. Our objective is to deploy the state of the a...